Scorpion Therapeutics, Inc.

1. Lawsuits

1 case: 1 closed (disposition not in docket feed)

Arbella Therapeutics, LLC v. Scorpion Therapeutics, Inc. closed

District Court, D. Massachusetts · No. 1:20-cv-12142 · Filed Nov 30, 2020 · Closed May 27, 2021

Role of Scorpion Therapeutics, Inc.: Defendant · Outcome: Terminated 2021-05-27 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

exact company name; court in the issuer's state (MA)

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:13 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Scorpion Therapeutics, Inc...

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:13 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

5 differences found between the filings for Scorpion Therapeutics, Inc. (compared 3 filings on Oct 24, 2026)

Note · Nov 20, 2020 – Dec 7, 2020

Form D filed 17 days after the first sale — Scorpion Therapeutics, Inc.

The filing says the first sale was Nov 20, 2020. The Form D was filed Dec 7, 2020 — 17 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 2 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Dec 7, 2020 ↗Scorpion Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · Dec 7, 2020 ↗ (Dec 7, 2020)
Scorpion Therapeutics, Inc. — PartnerFacts page ↗ (Jul 16, 2024)

Note · Apr 23, 2020 – May 19, 2020

Form D filed 26 days after the first sale — Scorpion Therapeutics, Inc.

The filing says the first sale was Apr 23, 2020. The Form D was filed May 19, 2020 — 26 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 11 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · May 19, 2020 ↗Scorpion Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · May 19, 2020 ↗ (May 19, 2020)
Scorpion Therapeutics, Inc. — PartnerFacts page ↗ (Jul 16, 2024)

Note · Jul 1, 2024 – Jul 16, 2024

No amendment in the last 12 months on an offering that may still be open — Scorpion Therapeutics, Inc. (latest filing Jul 16, 2024)

The latest filing for this offering is dated Jul 16, 2024 (first sale Jul 1, 2024). It reports $125,694,186 sold of $150,000,002 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Jul 16, 2024 ↗Scorpion Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · Jul 16, 2024 ↗ (Jul 16, 2024)
Scorpion Therapeutics, Inc. — PartnerFacts page ↗ (Jul 16, 2024)

Note · Nov 20, 2020 – Dec 7, 2020

No amendment in the last 12 months on an offering that may still be open — Scorpion Therapeutics, Inc. (latest filing Dec 7, 2020)

The latest filing for this offering is dated Dec 7, 2020 (first sale Nov 20, 2020). It reports $146,999,977 sold of an indefinite amount offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Dec 7, 2020 ↗Scorpion Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · Dec 7, 2020 ↗ (Dec 7, 2020)
Scorpion Therapeutics, Inc. — PartnerFacts page ↗ (Jul 16, 2024)

Note · Apr 23, 2020 – May 19, 2020

No amendment in the last 12 months on an offering that may still be open — Scorpion Therapeutics, Inc. (latest filing May 19, 2020)

The latest filing for this offering is dated May 19, 2020 (first sale Apr 23, 2020). It reports $24,681,250 sold of an indefinite amount offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · May 19, 2020 ↗Scorpion Therapeutics, Inc. — PartnerFacts page ↗

Sources

Form D · May 19, 2020 ↗ (May 19, 2020)
Scorpion Therapeutics, Inc. — PartnerFacts page ↗ (Jul 16, 2024)

What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

None reported on 3 offerings — no sales commissions, finder's fees or proceeds to insiders

Per-offering detail

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Jul 16, 2024 D File 021-518868	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 7, 2020 D File 021-382478	$0	$0	$0	None listed on this filing	EDGAR ↗
May 19, 2020 D File 021-367229	$0	$0	$0	None listed on this filing	EDGAR ↗

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

File no.	Original Form D	Latest filing	Offered (latest)	Sold (latest)	Industry (latest)
021-518868	Jul 16, 2024 EDGAR ↗	Jul 16, 2024 D EDGAR ↗	$150,000,002	$125,694,186	Biotechnology
021-382478	Dec 7, 2020 EDGAR ↗	Dec 7, 2020 D EDGAR ↗	Indefinite	$146,999,977	Biotechnology
021-367229	May 19, 2020 EDGAR ↗	May 19, 2020 D EDGAR ↗	Indefinite	$24,681,250	Biotechnology

Filing	Form D filed Jul 16, 2024 SEC file no. 021-518868 · accession 0000950123-24-006593
Raise progress	$125,694,186 sold of $150,000,002 offered (84%) · $24,305,816 remaining · first sale Jul 1, 2024
Filing timing	Date of first sale: Jul 1, 2024 · Form D filed: Jul 16, 2024 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	845 days (2.3 years)
Annual amendments	Issuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	38 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity
Entity details	Organized in DELAWARE · formed 2020 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Adam Friedman, Chief Executive Officer (Jul 16, 2024)
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $150,000,002. Typical range: $2,000,000–$19,999,994. Investors: 38. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Filing	Form D filed Dec 7, 2020 SEC file no. 021-382478 · accession 0001811858-20-000003
Raise progress	$146,999,977 sold of Indefinite offered · Indefinite remaining · first sale Nov 20, 2020
Filing timing	Date of first sale: Nov 20, 2020 · Form D filed: Dec 7, 2020 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	2,164 days (5.9 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	22 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity
Entity details	Organized in DELAWARE · formed 2020 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Peter Joseph Campisi, Jr., Secretary (Dec 7, 2020)
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 22. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Filing	Form D filed May 19, 2020 SEC file no. 021-367229 · accession 0001811858-20-000001
Raise progress	$24,681,250 sold of Indefinite offered · Indefinite remaining · first sale Apr 23, 2020
Filing timing	Date of first sale: Apr 23, 2020 · Form D filed: May 19, 2020 (26 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	2,375 days (6.5 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	11 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity
Entity details	Organized in DELAWARE · formed 2020 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Peter Joseph Campisi, Jr., Secretary and General Counsel (May 18, 2020)
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 11. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Name	Relationship	Address state	On filings (first → last)	Also listed on
AF Adam Friedman	Executive Officer, Director	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	2 other issuers
AV Amanda Valentino	Executive Officer	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	—
AF Andrew Fedder	Executive Officer	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	1 other issuer
AG Arjun Goyal	Director	MA	Dec 7, 2020 → Jul 16, 2024 on 2 of 3 filings listed on the latest filing	9 other issuers
BP Brian Piper	Executive Officer	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	2 other issuers
DS Darrin Stuart	Executive Officer	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	—
EJ Erica Jackson	Executive Officer	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	—
JF Jean-Francois Formela	Director	MA	Dec 7, 2020 → Jul 16, 2024 on 2 of 3 filings listed on the latest filing	25 other issuers
JA Jeffrey Albers	Director	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	4 other issuers
KF Keith Flaherty	Director	MA	Dec 7, 2020 → Jul 16, 2024 on 2 of 3 filings listed on the latest filing	3 other issuers
MC Mark Chao	Executive Officer	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	—
ON Oleg Nodelman	Director	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	11 other issuers
OS Otello Stampacchia	Director	MA	Dec 7, 2020 → Jul 16, 2024 on 2 of 3 filings listed on the latest filing	6 other issuers
SS Saurabh Saha	Director	MA	Jul 16, 2024 on 1 of 3 filings listed on the latest filing	—
SC Shelley Chu	Director	MA	Dec 7, 2020 → Jul 16, 2024 on 2 of 3 filings listed on the latest filing	8 other issuers
GG Gary Glick person page: Gary D. Glick	Executive Officer, Director	MA	May 19, 2020 → Dec 7, 2020 on 2 of 3 filings not listed on the latest filing (Jul 16, 2024)	7 other issuers
PC Peter Joseph Campisi, Jr.	Executive Officer	MA	May 19, 2020 → Dec 7, 2020 on 2 of 3 filings not listed on the latest filing (Jul 16, 2024)	—

The short version

What the community is saying

Key records

1. Lawsuits

2. Regulatory actions

3. Bankruptcies

4. Differences between public sources

Form D filed 17 days after the first sale — Scorpion Therapeutics, Inc.

Form D filed 26 days after the first sale — Scorpion Therapeutics, Inc.

No amendment in the last 12 months on an offering that may still be open — Scorpion Therapeutics, Inc. (latest filing Jul 16, 2024)

No amendment in the last 12 months on an offering that may still be open — Scorpion Therapeutics, Inc. (latest filing Dec 7, 2020)

No amendment in the last 12 months on an offering that may still be open — Scorpion Therapeutics, Inc. (latest filing May 19, 2020)

5. Money to insiders

Offerings (SEC Form D)

Key people 17

Connections

Other offering types (Regulation A and Regulation Crowdfunding)

Adviser registration (Form ADV)

Meta advertising

Public profiles

Corrections log

Email me the full report

What do you want to do?

Request a correction

Sponsor response

Claim this profile (sponsors)

Look further

Social and web

Courts

Securities regulators

Business registries